logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy appoints a chief commercial officer and president for its US division

Moataz Karmalawy has served as general manager of the Worldwide Particle Therapy Business for Varian Medical Systems, the world's largest manufacturer of radiotherapy equipment for 12 years

US handshake
Before joining Varian Medical, Karmalawy worked at Philips Medical Systems for 10 years where he served in several senior executive roles

Advanced Oncotherapy PLC (LON:AVO) shares jumped higher on Tuesday as the group announced the appointment of Moataz Karmalawy as its chief commercial officer and president of its US division with immediate effect.

The AIM-listed developer of a next-generation proton therapy system for cancer treatment noted that Karmalawy has served as general manager of the Worldwide Particle Therapy Business for Varian Medical Systems Inc., the world's largest manufacturer of radiotherapy equipment for 12 years

READ: Advanced Oncotherapy rises as it obtains international quality standard for LIGHT system

The group pointed out that, whilst at Varian Medical, Karmalawy integrated the acquired proton therapy business into the division, before growing the order book to in excess of US$1bn and achieving a 50% market share of the global particle therapy products market.

Before joining Varian Medical, Karmalawy worked at Philips Medical Systems Inc. for 10 years where he served in several senior executive roles, it added.

Commenting on his appointment, Karmalawy, said: "Advanced Oncotherapy stands out as an incredibly exciting opportunity within the proton therapy market. The global capacity to treat patients with proton therapy has been disappointingly low due to the high cost of traditional proton therapy technologies. 

"As a result, only 1% of patients eligible for radiotherapy are being treated with proton therapy. Advanced Oncotherapy's technology will make this treatment more affordable and accessible to cancer patients worldwide and the LIGHT system has a number of technical advantages to existing technology that will deliver better patient outcomes and offer an accuracy and adjustability beyond legacy technologies."

Advanced Oncotherapy pointed out that his appointment is a non-board appointment.

In afternoon trading, shares in Advanced Oncotherapy were 10% higher at 43.50p.

 -- Adds share price -- 

Quick facts: Advanced Oncotherapy PLC

Price: 37.5 GBX

LSE:AVO
Market: LSE
Market Cap: £91.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: VR Education's ENGAGE platform to be included in new 5G VR...

Headlines from the Proactive UK newsroom. VR Education’s (LON:VRE) Engage platform has been chosen as an embedded title in a new 5G virtual reality headset being developed by a consortium of Deutsche Telekom, Qualcomm and XRSPACE. The new headset is due to launch in...

1 week, 3 days ago

RNS

Holding(s) in Company

1 week, 4 days ago

Total Voting Rights

2 weeks, 1 day ago

Holding(s) in Company

2 weeks, 2 days ago

Total Voting Rights

on 6/11/19

Change of Broker

on 10/10/19

Total Voting Rights

on 30/9/19

2 min read